Stay updated with breaking news from Eric Dobmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) – Equities research analysts at Wedbush issued their Q1 2024 earnings per share (EPS) estimates for shares of Chinook Therapeutics in a research note issued to investors on Wednesday, May 10th. Wedbush analyst L. Chico anticipates that the company will post earnings of ($0.81) per share for the […]
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03), Briefing.com reports. Chinook Therapeutics had a negative net margin of 3,065.68% and a negative return on equity of 40.61%. The business had revenue […]
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) issued its quarterly earnings data on Tuesday. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.03), Briefing.com reports. Chinook Therapeutics had a negative net margin of 3,065.68% and a negative return on equity of 40.61%. The firm had revenue of $1.83 million […]
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier sold 23,800 shares of the stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $21.58, for a total transaction of $513,604.00. Following the transaction, the chief executive officer now directly owns 302,338 shares in the […]
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) fell 4.1% on Thursday following insider selling activity. The company traded as low as $21.42 and last traded at $21.48. 106,804 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 544,286 shares. The stock had previously closed at $22.41. Specifically, Director […]